JP Morgan: Maintains WuXi AppTec (02359) as Top CXO Pick, Keeps "Overweight" Rating

Stock News

Sep 29, 2025

JP Morgan released a research report stating that it continues to list WuXi AppTec (02359) as its top pick in China's CXO industry. The firm noted that the company is China's largest contract research, development and manufacturing organization by revenue and expressed optimism about its business fundamentals. JP Morgan believes competition in the small molecule CRDMO sector remains relatively moderate, while WuXi AppTec's TIDES business continues to demonstrate strong growth momentum. The firm maintains its "Overweight" rating with a target price of HK$138.

JP Morgan recently participated in WuXi AppTec's 2025 Investor Day, which coincided with President Trump's announcement of plans to impose 100% tariffs on imported branded and patent drugs starting October 1st, unless the relevant pharmaceutical companies have begun construction of production facilities in the United States.

JP Morgan anticipates that this drug tariff policy will not have a direct impact on Chinese CDMO companies such as WuXi AppTec, as customers typically bear the responsibility for tariff payments. Additionally, WuXi AppTec is expanding its U.S. production capacity to meet client demand for localized manufacturing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169841580"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169841580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169841580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169841580","market":"other","top_or_hot":-1,"title":"JP Morgan: Maintains WuXi AppTec (02359) as Top CXO Pick, Keeps \"Overweight\" Rating","media":"Stock News","content":"<p>JP Morgan released a research report stating that it continues to list WuXi AppTec (02359) as its top pick in China's CXO industry. The firm noted that the company is China's largest contract research, development and manufacturing organization by revenue and expressed optimism about its business fundamentals. JP Morgan believes competition in the small molecule CRDMO sector remains relatively moderate, while WuXi AppTec's TIDES business continues to demonstrate strong growth momentum. The firm maintains its \"Overweight\" rating with a target price of HK$138.</p>\n<p>JP Morgan recently participated in WuXi AppTec's 2025 Investor Day, which coincided with President Trump's announcement of plans to impose 100% tariffs on imported branded and patent drugs starting October 1st, unless the relevant pharmaceutical companies have begun construction of production facilities in the United States.</p>\n<p>JP Morgan anticipates that this drug tariff policy will not have a direct impact on Chinese CDMO companies such as WuXi AppTec, as customers typically bear the responsibility for tariff payments. Additionally, WuXi AppTec is expanding its U.S. production capacity to meet client demand for localized manufacturing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JP Morgan: Maintains WuXi AppTec (02359) as Top CXO Pick, Keeps \"Overweight\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJP Morgan: Maintains WuXi AppTec (02359) as Top CXO Pick, Keeps \"Overweight\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-29 13:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JP Morgan released a research report stating that it continues to list WuXi AppTec (02359) as its top pick in China's CXO industry. The firm noted that the company is China's largest contract research, development and manufacturing organization by revenue and expressed optimism about its business fundamentals. JP Morgan believes competition in the small molecule CRDMO sector remains relatively moderate, while WuXi AppTec's TIDES business continues to demonstrate strong growth momentum. The firm maintains its \"Overweight\" rating with a target price of HK$138.</p>\n<p>JP Morgan recently participated in WuXi AppTec's 2025 Investor Day, which coincided with President Trump's announcement of plans to impose 100% tariffs on imported branded and patent drugs starting October 1st, unless the relevant pharmaceutical companies have begun construction of production facilities in the United States.</p>\n<p>JP Morgan anticipates that this drug tariff policy will not have a direct impact on Chinese CDMO companies such as WuXi AppTec, as customers typically bear the responsibility for tariff payments. Additionally, WuXi AppTec is expanding its U.S. production capacity to meet client demand for localized manufacturing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242644610.SGD","symbol_name":"Fidelity China Innovation A-ACC-SGD","start_time":0,"source_url":"","article_id":"1169841580","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169841580","pubTimestamp":1759125530,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JP Morgan released a research report stating that it continues to list WuXi AppTec (02359) as its top pick in China's CXO industry. The firm noted that the company is China's largest contract...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK0216":"研究试验","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","BK1141":"生命科学工具和服务","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK1576":"医药外包概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","CXO":"康休","02359":"药明康德","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1583":"高瓴概念"},"translate_title":"摩根大通：维持药明康德(02359)为CXO首选，维持“跑赢大盘”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1,"CXO":1},"content_text":"JP Morgan released a research report stating that it continues to list WuXi AppTec (02359) as its top pick in China's CXO industry. The firm noted that the company is China's largest contract research, development and manufacturing organization by revenue and expressed optimism about its business fundamentals. JP Morgan believes competition in the small molecule CRDMO sector remains relatively moderate, while WuXi AppTec's TIDES business continues to demonstrate strong growth momentum. The firm maintains its \"Overweight\" rating with a target price of HK$138.\nJP Morgan recently participated in WuXi AppTec's 2025 Investor Day, which coincided with President Trump's announcement of plans to impose 100% tariffs on imported branded and patent drugs starting October 1st, unless the relevant pharmaceutical companies have begun construction of production facilities in the United States.\nJP Morgan anticipates that this drug tariff policy will not have a direct impact on Chinese CDMO companies such as WuXi AppTec, as customers typically bear the responsibility for tariff payments. Additionally, WuXi AppTec is expanding its U.S. production capacity to meet client demand for localized manufacturing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}